Shanghai – September 20, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Atlanta and Los Angeles – September 20, 2026 -- StimCardio Medical reported that patients treated with non-invasive median nerve stimulation (MNS) after atrial fibrillation (AF) ablation showed 90.0% freedom from atrial arrhythmias at six months, compared with 80.8% for those receiving sham treatment, though the difference did not reach statistical significance. The randomized, double-blind, sham-controlled NeuroPulse pilot study was presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the peer-reviewed journal Heart Rhythm.

Seoul – September 16, 2026 -- A phase III trial of tambotatug pelitecan (Tam-Peli, YL201), an anti-B7-H3 antibody-drug conjugate, cut the risk of death by 54% compared with standard-of-care topotecan in patients with relapsed small-cell lung cancer (SCLC), according to data presented at the IASLC 2026 World Conference on Lung Cancer.

Seoul – September 16, 2026 -- Risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, reduced the risk of death by 54% compared with topotecan in patients with relapsed small-cell lung cancer, according to Phase III ARTEMIS-008 trial results presented at the IASLC 2026 World Conference on Lung Cancer.

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.